Mead Johnson Desyrel exclusivity
Firm resubmits exclusivity request and could be preparing for court challenge if FDA denies again. Mead Johnson maintains that Desyrel final approval did not come until mid-January or early February 1982, qualifying the product for 10 years of exclusivity protection under the Waxman/Hatch Act. FDA maintains the product was approved on Dec. 24, 1981 which negates the exclusivity claim ("The Pink Sheet" Sept. 2, T&G-1).
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.